Related Experiment Video
Updated: May 13, 2026
Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
Published on: February 2, 2024
Sunitinib malate for the treatment of pancreas malignancies--where does it fit?
Pavan Mankal1, Eileen O'Reilly
1Columbia University College of Physicians and Surgeons, St. Luke's-Roosevelt Hospital Center, Department of Medicine, New York, USA.
Introduction:
Sunitinib , a broad-spectrum multikinase inhibitor, was recently approved for use in progressive, well-differentiated pancreatic neuroendocrine tumors (pNETs). Its mechanism of action affects various signaling cascades involving antiangiogenesis and tumor proliferation, including vascular endothelial growth factors and platelet-derived growth factors.
Areas Covered:
In this article, we review sunitinib's mechanism of action at a molecular level and review key preclinical and clinical studies for pNETs and more limited data regarding sunitinib's evaluation in pancreas adenocarcinoma. The data for sunitinib in pNETs are placed in the context of the changing landscape of therapeutic options for this cancer, and relevant ongoing clinical trials and future directions are highlighted.
Expert Opinion:
Sunitinib malate has become integrated into routine clinical management for pNETs; however, its role in pancreas adenocarcinoma is not established.
Insights
Sunitinib is approved for pancreatic neuroendocrine tumors (pNETs), targeting pathways like antiangiogenesis. Its effectiveness in pancreas adenocarcinoma requires further investigation.
Area of Science:
- Oncology
- Pharmacology
Background:
- Sunitinib, a multikinase inhibitor, is approved for progressive, well-differentiated pancreatic neuroendocrine tumors (pNETs).
- Its mechanism involves inhibiting signaling cascades related to antiangiogenesis and tumor proliferation, including VEGF and PDGF pathways.
Purpose of the Study:
- To review sunitinib's molecular mechanism of action.
- To evaluate preclinical and clinical data for sunitinib in pNETs and pancreas adenocarcinoma.
- To contextualize sunitinib's role within evolving pNET therapeutics and highlight future directions.
Main Methods:
- Review of molecular mechanisms.
- Analysis of preclinical and clinical studies in pNETs.
- Limited data review for pancreas adenocarcinoma.
Main Results:
- Sunitinib is established in pNET clinical management.
- Data for sunitinib in pancreas adenocarcinoma is limited.
Conclusions:
- Sunitinib malate is a standard treatment for pNETs.
- The role of sunitinib in pancreas adenocarcinoma remains undetermined.
